Navigation Links
Patients More Willing To Use Self-Injectable HIV Therapy Than Anticipated

Recent study shows that HIV patients are more willing to consider and use self-injectable therapy than many physicians anticipate // .

Initial results from the OpenMind study, the largest behavioural study to look at both patients' and physicians' perceptions of HIV care in treatment-experienced patients, were revealed today at EACS.

The findings are anticipated to help physicians implement improved care to HIV patients and help pave the way for better acceptance and integration of other new innovative drugs such as monoclonal antibodies that are increasingly being developed for the management of HIV and other diseases.

The study was conceived to look at attitudes to FUZEON (enfuvirtide), the first approved HIV fusion inhibitor, and an important option for treatment-experienced patients who face HIV resistance. FUZEON presents unique challenges because it is the first self-injectable antiretroviral whereas all other treatments are oral.

It was found that 76% of patients would consider using a self-injectable HIV therapy if their physician recommended it. However, only 28% of patients who are potentially eligible for FUZEON had actually discussed this injectable option with their physicians. Only 10% of eligible patients were currently prescribed FUZEON, despite the fact that it is recommended in key international HIV treatment guidelines.

This study also identifies some of the main reasons why many physicians may be reluctant to prescribe a treatment of proven efficacy and safety. The reasons include; the physicians' perception that patients would be reluctant to use a self-injectable therapy, the physicians' opinion that the patient would not be able to incorporate FUZEON into their lifestyle and the potential misconception that FUZEON is not appropriately recommended in guidelines.

Rob Horne, Professor of Psychology at the University of Brighton and OpenMind study author, said, "These new insights from th e OpenMind study will enable us to develop tools to facilitate more informed decisions by both patient and physician."

The study also shows that physicians' own experiences and attitudes towards self-injection are a significant motivator for its use. Physicians with considerable FUZEON experience were significantly more likely to justify using self-injectable therapy in terms of time and resources and were less likely to doubt its efficacy relative to oral therapies, when compared to physicians less experienced with this type of treatment.

The authors claim that these findings potentially have far reaching implications across a whole range of therapeutic areas.


'"/>




Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... Greifensee, Switzerland (PRWEB) , ... April 25, 2017 ... ... product innovation targets, they rely on contracted partners to help with process innovation ... years of combined drug formulation experience along with state-of-the-art analytical equipment in support ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading ... patient care management module. Using this new feature, sleep physicians can now predict ... on continuous positive airway pressure (CPAP), oral, or other forms of sleep apnea ...
(Date:4/24/2017)... ... April 24, 2017 , ... Emmanuel College is ... professionals advance their careers. Beginning in the fall of 2017, Emmanuel’s program will allow ... as few as 16 months and for as little as $14,528. These changes will ...
(Date:4/24/2017)... ... April 24, 2017 , ... As part of the nationwide ... honor the victims of the Holocaust and Nazi persecution, Center for Medicine after ... Auschwitz on its CMATH Champions trip to Germany and Poland next week. , The ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Sean Fay ... Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold ... any other marketer in the last 25 years. , Now, due to changes in ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... announced that it will be participating in the Deutsche ... InterContinental Hotel in Boston, Massachusetts ... at 11:20 a.m. Eastern Time. A live ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com .  The ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... from the Company,s consumer product development program, based ... the Society for Investigative Dermatology (SID) 76 th ... advance and promote the sciences relevant to skin ...
(Date:4/20/2017)... April 20, 2017  CVS Pharmacy, the retail ... a new store design to enhance the retail ... food, health-focused products and expanded beauty selections paired ... customers discover new offerings. Together with its innovative ... of the customer experience at CVS Pharmacy.  ...
Breaking Medicine Technology: